Form 4: RA Capital Management Reports Acquisition of Stock Options in Cidara Therapeutics

RA Capital Management and related parties report the acquisition of stock options in Cidara Therapeutics, Inc. on July 18, 2024.

Summary

• RA Capital Management, L.P., along with related entities and individuals, filed a Form 4 detailing changes in beneficial ownership of Cidara Therapeutics, Inc. securities.
• The report indicates the acquisition of 2,125 stock options with an exercise price of $1 on July 18, 2024.
• The options vest on the earlier of the first anniversary of the grant date or the day prior to the Issuer's 2025 annual meeting of stockholders.
• The reporting persons, including RA Capital Management, RA Capital Healthcare Fund, Peter Kolchinsky, and Rajeev Shah, disclaim beneficial ownership of the options and underlying common stock, except to the extent of their respective pecuniary interest.
• Laura Tadvalkar, a Managing Director of RA Capital Management, holds the option for the benefit of the Fund and is obligated to turn over any proceeds to offset advisory fees.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing a transaction. The acquisition of options could be seen as a slightly positive signal, but the disclaimers of beneficial ownership temper this.

Positives

• The acquisition of stock options by a significant shareholder like RA Capital Management could be interpreted as a sign of confidence in Cidara Therapeutics' future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders and major shareholders. This filing indicates changes in RA Capital Management's holdings in Cidara Therapeutics.

Stakeholder Impact

• The acquisition of stock options by RA Capital Management may influence investor perception of Cidara Therapeutics.

Key Dates